Drug Profile
Research programme: organic boron compounds - Pfizer/DNDi/Pace University/SCYNEXIS/WuXi AppTec
Latest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator Anacor Pharmaceuticals; Drugs for Neglected Diseases Initiative Foundation; London School of Hygiene & Tropical Medicine; Pace University; SCYNEXIS; University of Antwerp; WuXi AppTec
- Developer Anacor Pharmaceuticals; Drugs for Neglected Diseases Initiative Foundation; London School of Hygiene & Tropical Medicine; Pace University; Pfizer; SCYNEXIS; University of Antwerp; WuXi AppTec
- Class Organic boron compounds
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Leishmaniasis; Trypanosomiasis
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for preclinical development in Leishmaniasis in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Trypanosomiasis in USA (PO)
- 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer